Market closed
NanoViricides/$NNVC
NanoViricides shares are trading higher after the company announced progress in its antiviral drug trials for measles and MPox.
12 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NanoViricides
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Ticker
$NNVC
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
7
ISIN
US6300873022
Website
NanoViricides Metrics
BasicAdvanced
$20M
-
-$0.72
1.35
-
Price and volume
Market cap
$20M
Beta
1.35
52-week high
$1.48
52-week low
$0.94
Average daily volume
111K
Financial strength
Current ratio
3.439
Quick ratio
3.343
Interest coverage (TTM)
-63,937.24%
Management effectiveness
Return on assets (TTM)
-47.69%
Return on equity (TTM)
-82.01%
Valuation
Price to book
1.88
Price to tangible book (TTM)
1.94
Price to free cash flow (TTM)
-1.945
Growth
Earnings per share change (TTM)
-10.47%
3-year earnings per share growth (CAGR)
-2.22%
NanoViricides News
AllArticlesVideos
NanoViricides progresses antiviral portfolio as measles and MPox threats rise
Proactive Investors·14 hours ago
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRC
Proactive Investors·7 days ago
NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC
Newsfile Corp·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for NanoViricides stock?
NanoViricides (NNVC) has a market cap of $20M as of May 15, 2025.
What is the P/E ratio for NanoViricides stock?
The price to earnings (P/E) ratio for NanoViricides (NNVC) stock is 0 as of May 15, 2025.
Does NanoViricides stock pay dividends?
No, NanoViricides (NNVC) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next NanoViricides dividend payment date?
NanoViricides (NNVC) stock does not pay dividends to its shareholders.
What is the beta indicator for NanoViricides?
NanoViricides (NNVC) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.